Background: NMDA receptor specifically NR2B subunit plays a major role in eliptogenisis. Antagonists at NR2B receptor site have importance in design of anticonvulsant agents. Some quinazolinones and oxazepine have inherent drug likeliness for anticonvulsant activity. In this research work in silico biological activity spectrum (BAS), ADME prediction, Log P predictions and docking was carried out. A library of quinazolinones with oxazepinone ring was designed, from this library 3-(6-halo-2-methyl-oxoquinazolin-3-(4H-yl)-2-(substituted phenyl)-2, 3-dihydro-1,3-oxazepine-4,7-dione (AMQ 1-5 ) were prioritized for actual synthesis and pharmacological screening for NMDA receptor antagonistic activity. Method: The prioritized molecules were synthesized and characterized by melting point, IR, 1 H-NMR, TLC and elemental analysis. AOT was performed to determine LD 50 of prioritized molecules, further compounds were evaluated for their in vivo antagonistic activity on NMDA induced convulsions in mice. Result: Prioritized molecules AMQ 1-5 exhibited potent antagonistic activity on NMDA receptor. Conclusion: The compound of series AMQ 1 and AMQ 5 were showed significant activity compared to standard memantine used in the assay.
INTRODUCTION
A library of quinazolinone with oxazepinone ring was in silico screened for biological activity spectrum and partition coefficient predictions (Log P) using PASS server and mol inspiration software respectively. This gave biological activity score 1 (BAS) for anticonvulsant activity for NMDA inhibition mechanism and predicted Log P value (p Log P). Quinazolinone nucleus with oxazepinone ring was selected in this research due to its significant anticonvulsant potential [2] [3] [4] [5] [6] [7] [8] [9] Docking was performed on AutoDock 1.5.3 software for screening of molecule. Synthesized molecules were evaluated by IR, 1 H-NMR, Mass spectroscopy and elemental analysis. Further synthesized prioritized molecules were evaluated for in vivo acute oral toxicity (AOT) and anticonvulsant activity. Anticonvulsant activity was established in antagonism of test compounds in NMDA induced convulsion methanistic model. Acute Oral Toxicity (AOT) was carried to determine LD 50 of the prioritized molecules according to OECD guideline 425.
Further molecules were evaluated from 300-2000 mg/kg for AOT studies.
MATERIALS AND METHODS

In silico screening
Molecules were converted from 2-D chemsketch files into 3-D mol files using Marvin Sketch and then uploaded on PASS online server to get BAS prediction. Predicted Log P (pLogP) values were obtained from molinspiration online software 10 and further ADME prediction were obtained PreADMET online server.
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BAS Activity Prediction: The compounds from the quinazolinone with oxazepinone ring AMQ 1-5 series were subjected to predict BAS activity. These values are shown in Table 1 , 2. Structures of these compounds are given in Figure 1 .
Log P prediction: The ranges of log P values used for prioritization are shown in Table 1, 2. ii) ADME predictions 11 a) MDCK cell permeability: The ranges of MDCK cell permeability used for in silico prioritization of molecule are shown in Table 2 . 
Docking protocol
Computer-assisted simulated docking experiments were carried out in Auto Dock Tools 1.5.4 for prioritized molecules. Validation of protein subunit was done by the online server www.nihserver.mbi.ucla.edu/SAVES. The ChemOffice software was used to draw molecular structures and for the conversion of the 2D structure to 3D mol files.
Selection of the Protein File
For the docking purpose the PDB file 3QEL was selected after evaluating several files from the Protein Database bank www.rcsb.org. (Table 3) Structure Validation of the Enzyme
The errata report, Ramachandran plot & mol probidity ramachandran plot was obtained from the NIH MBI sever for evaluation of protein structures and are given in Figure  2 , Figure 3 and Figure 4 . All chemicals were purchased from Sigma Aldrich, SD Fine, Spectrochem and Merck. Yields refer to purified products and are not optimized
Synthesis of Schiff bases
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A mixture of 0.0l mole of 3-amino-2-methylquinazolin-4(3H)-one and 0.0l mole of aldehyde in (10 ml) absolute ethanol was refluxed in water bath for (30 min ) then left to cool in ice -water. The solid was filtered, washed with 2%HCl and water. Recrystallized the precipitate twice from ethanol. Figure 1 4 (s, 1H, CH of quinazolinone) 
3-(6-bromo-methyl-oxoquinazolin-3(4H)-yl)-2-(4-nitrophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione. (AMQ
3-(6-bromo-methyl-oxoquinazolin-3(4H)-yl)-2-(4-bromophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione. (AMQ
3-(6-bromo-methyl-oxoquinazolin-3(4H)-yl)-2-(2-nitrophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione. (AMQ 4 )
3-(6-bromo-methyl-oxoquinazolin-3(4H)-yl)-2-(4-
methoxyphenyl
Pharmacological screening
Swiss albino mice of either sex weighing between 20-25 gm, obtained from National Toxicological Centre, Pune, India. During the course of the experiment, the general behaviour of the animal was normal. [21] [22] [23] [24] To ensure proper testing, prior to the testing for 24hr period mice had free access to food and water. All the experimental protocols were approved by the institutional animal ethical committee according to OECD guidlines 425.
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Acute Oral Toxicity (AOT) Studies AOT studies were performed to determine the LD 50 of the compounds following the OECD 425 guidelines. According to OECD guidelines the dose should be 300-2000 mg/kg for AOT study. 22 Animal were observed for 4 hr and also observed for salivation, lacrimation and motor activity of animals. Further animals were observed for 24 hr and note the death rate of animals.
Antagonism of NMDA induced convulsions (Anticonvulsant Activity)
Six mice of either sex with a weight of 20 to 25 g were treated with test compound or the standard (Memantine) by oral or subcutaneous administration. Controls received the vehicle only 30 minutes after subcutaneous (s. c.) or 60 minutes after p.o treatment the animals were injected with subcutaneous dose of 125 mg/kg 23, 24 NMDA (N-methyl-D-aspartate). During the next 120 minutes the occurrence of clonic seizures, tonic seizures & death was recorded at dose levels of the test 100 mg/kg to 4000 mg/kg. Test group received synthesized (test) compounds (AMQ 1-5 ). Standard group received Memantine 10 mg/kg. (Table 4) 
RESULT AND DISCUSSION
In silico study was performed by Biological activity prediction Spectrum (BAS), Log P, Auto dock tool 1.5.4 and Pre ADMET software. Novel series of 4-OxoQuinazolines with oxazepinone (AMQ 1-5 ) ring showed the interaction with ILE335:N, GLN110:NE2, PHE113:N and GlN110:NE2. AMQ 1, AMQ 2 and AMQ 3 molecules showed good hydrogen bonding with receptor. In general the obtained scores are in between -10.5 and -15.56 and compared with standard Memantine with the score of -13.63. All the ligands docked deeply within the binding pocket region suggested their shape complementarily with 3QEL. LogP values are between 2.99 to 3.87 suggested that prioritized molecules can cross Blood brain barrier (BBB). Further synthesized compounds of series AMQ 1-5 were evaluated for pharmacological screening by acute oral toxicity (AOT) and anticonvulsant activity on NMDA receptor by mechanistic model. AOT was carried at a dose of 300-2000 mg/kg on mice for determining the LD 50 of compounds based on OECD 425 guidelines. On the basis of AOT (shown in table) the dose for anticonvulsant activity was chosen between 50-400 mg/kg. Compound AMQ 1 and AMQ 5 showed 60.5% and 85% of percentage potency respectively as compared with Memantine taken as standard in the anticonvulsant pharmacological screening.
CONCLUSION
Compounds AMQ 1 and AMQ 5 can serve as lead for as NMDA receptor antagonists for anticonvulsant activity.
